FDA's 2026 Move to Expand TRT for Low Libido

For decades, testosterone replacement therapy (TRT) has been formally approved by the U.S. Food and Drug Administration only for men with classical hypogonadism, meaning low testosterone caused by a clear medical condition such as a testicular injury, pituitary disorder, or genetic syndrome. In April 2026, that long standing limit took a notable step toward changing.

What the FDA Announced

On April 20, 2026, the FDA published a Federal Register notice titled "Potential New Indication for Testosterone Replacement Therapy" (Federal Register, 2026). In it, the agency acknowledged that emerging clinical evidence supports a possible new use for TRT: treating low libido in men with idiopathic hypogonadism, a condition where testosterone levels are low without an identifiable structural or genetic cause.

The notice invites holders of approved TRT new drug applications (NDAs) to contact the agency by April 30, 2026, about submitting a supplemental NDA for this new indication (FDA, 2026). In plain language, the FDA is signaling that drugmakers can now begin the process of formally adding low libido to the list of approved uses for testosterone products.

How We Got Here

The April notice did not come out of nowhere. In December 2025, an FDA expert panel reviewed years of clinical data on TRT, including the landmark TRAVERSE cardiovascular safety trial. The panel recommended easing several restrictions on testosterone therapy, including the removal of TRT's status as a controlled substance and a broadening of the patient population eligible for treatment (RAPS, 2025).

That recommendation followed a February 2025 FDA decision to remove the cardiovascular black box warning from testosterone product labels, a warning that had discouraged many physicians and patients from pursuing therapy since 2015 (Healthline, 2025).

Who Could Benefit

If the new indication is formally approved, men with low testosterone and low libido but no identifiable cause of their hormone deficiency would have a clearly approved reason to seek TRT. Today, those patients often receive treatment off label, which can create insurance coverage challenges and inconsistent care.

The change would not turn testosterone into a lifestyle drug. The FDA still expects evidence of clinically low testosterone confirmed by morning blood draws, and the new indication would be tied specifically to symptomatic low libido.

What Patients Should Do Now

If you suspect low testosterone is affecting your sex drive, the path forward has not changed yet. Start with a qualified provider, get morning serum testosterone tested at least twice, and discuss symptoms in full. If the FDA finalizes the new indication later in 2026 or 2027, more men will likely qualify for therapy through standard insurance pathways.

You can find vetted TRT providers in your area through our TRT Locator directory.

Frequently Asked Questions

What is idiopathic hypogonadism?

Idiopathic hypogonadism means testosterone levels are clinically low with no identifiable structural or genetic cause — no testicular injury, no pituitary tumor, no known genetic syndrome. It is the most common form of low testosterone in otherwise healthy men and, until the FDA's April 2026 notice, was considered an off-label indication for TRT.

When will the FDA officially approve TRT for low libido?

The April 2026 Federal Register notice invited drugmakers to submit supplemental new drug applications for the new indication. Formal approval would require a full regulatory review. A realistic timeline is late 2026 to 2027, though the process could take longer depending on what data the FDA requires from applicants.

Does the proposed new indication mean any man can get TRT for low libido?

No. The proposed indication is specifically for men with both clinically low testosterone (confirmed by blood testing) and low libido as a documented symptom. TRT as a general treatment for low libido without confirmed low testosterone is not part of the proposal.

Will insurance cover TRT for low libido once the indication is approved?

Coverage depends on each plan. A formal FDA indication typically makes it easier to obtain prior authorization and reduces the likelihood of denial, but insurers can still set their own coverage criteria. Medicare and commercial plans would likely adopt updated criteria following final FDA action.

What should patients do now while the FDA review is underway?

Start with morning testosterone testing on at least two separate days. If levels are confirmed low and you have symptoms, work with a qualified provider who can document your case properly. Men who meet current clinical guidelines for hypogonadism can access TRT today — the new indication would expand access for those who fall outside current approved criteria.

Sources

• Federal Register: Potential New Indication for TRT
• FDA Takes Step Forward on Testosterone Therapy for Men (Healthline)
• FDA Signals Expansion of TRT for Idiopathic Hypogonadism (AJMC)

Find a TRT clinic near you →